# Neoadjuvant Nimotuzumab Plus Gemcitabine and Carboplatin in Unresectable Stage III Squamous Cell Lung Carcinoma

> **NCT02428764** · PHASE2 · WITHDRAWN · sponsor: **Sun Yat-sen University**

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Nimotuzumab
- **DRUG:** Gemcitabine
- **DRUG:** Carboplatin
- **PROCEDURE:** Surgery

## Key facts

- **NCT ID:** NCT02428764
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-04-01
- **Primary completion:** 2025-10-01
- **Final completion:** 2027-10-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No patients enrolled.
- **Last updated:** 2024-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02428764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02428764, "Neoadjuvant Nimotuzumab Plus Gemcitabine and Carboplatin in Unresectable Stage III Squamous Cell Lung Carcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02428764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*